Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Jon E, Stek"'
Autor:
Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen M. Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea L. Krick, Tina M. Sterling, Meihua Wang, Jason C. Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy K. Musey, the V110–029 Study Group
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2678-2690 (2021)
In most countries worldwide, pneumococcal conjugate vaccines have been included in the infant immunization program, resulting in a significant reduction in the burden of pneumococcal disease in children and adults. Shifting serotype distribution due
Externí odkaz:
https://doaj.org/article/30752f92ec314a7fbfcbcdcdba1371a0
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 1, Pp 191-196 (2021)
Background: Immune immaturity may put premature infants at increased risk for infections. DTaP-IPV-Hib-HepB vaccine (Vaxelis™), a hexavalent vaccine studied in >6,800 children, has acceptable safety and immunogenicity profiles generally similar to
Externí odkaz:
https://doaj.org/article/4f08c41c0af04d958a73b8c579d4cc1b
Autor:
Maria Petrecz, Camilo J. Acosta, Stephanie O. Klopfer, Barbara J. Kuter, Michelle G. Goveia, Jon E. Stek, Florian P. Schödel, Andrew W. Lee
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 426-432 (2019)
Safety and immunogenicity data from 5 clinical trials conducted in the US in children 12-to-23 months old where HAVi was administered alone or concomitantly with other pediatric vaccines (M-M-R®II, Varivax®, TRIPEDIA®, Prevnar®, ProQuad®, Pedvax
Externí odkaz:
https://doaj.org/article/4b3c986dcd8c4a55896ab3ff7c781e21
Autor:
Yoshiyuki Tanaka, Ruriko Yokokawa, Han Shi Rong, Hiroyuki Kishino, Jon E. Stek, Margaret Nelson, Jody Lawrence
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 6, Pp 1352-1358 (2017)
Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children. Most children are infected with rotavirus, and the health and economic burdens of rotavirus gastroenteritis on healthcare systems and families are considera
Externí odkaz:
https://doaj.org/article/40971ff0a49e4bff843b6461976b73a9
Autor:
Chitrananda Abeygunawardana, Jon E. Stek, Lucy Roalfe, Andrea Likos Krick, Tina M. Sterling, John Ervin, David Krupa, Meihua Wang, Charles P. Andrews, Temitope Folaranmi, Ulrike K. Buchwald, Jonathan Hartzel, Melvin A Kohn, Luwy Musey, Gretchen M. Tamms, Patrick Ajiboye, James T. Peterson, Jason C. Martin
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In most countries worldwide, pneumococcal conjugate vaccines have been included in the infant immunization program, resulting in a significant reduction in the burden of pneumococcal disease in children and adults. Shifting serotype distribution due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e49485286022b31a47c1099cf7e22811
https://doi.org/10.1080/21645515.2021.1888621
https://doi.org/10.1080/21645515.2021.1888621
Autor:
Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, Jake Jones, Jeffrey Quinones, Betul Ulukol, Ron Dagan, Peter Richmond, Jon E. Stek, Lizbeth Romero, Sandra Koseoglu, Gretchen Tamms, Richard McFetridge, Jianing Li, Kyeongmi Cheon, Luwy Musey, Natalie Banniettis, Kara Bickham
Publikováno v:
Vaccine.
Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee133831e497cecc4314aee909d6ff21
https://pubmed.ncbi.nlm.nih.gov/36621410
https://pubmed.ncbi.nlm.nih.gov/36621410
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background: Immune immaturity may put premature infants at increased risk for infections. DTaP-IPV-Hib-HepB vaccine (Vaxelis™), a hexavalent vaccine studied in >6,800 children, has acceptable safety and immunogenicity profiles generally similar to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0d6e5d114eea46da0f5a61a635137f
https://doi.org/10.1080/21645515.2020.1756668
https://doi.org/10.1080/21645515.2020.1756668
Autor:
Jon E. Stek, Jakub K. Simon, Jason C. Martin, Michelle G. Goveia, Stephanie O. Klopfer, Maria Petrecz
Publikováno v:
Vaccine. 39(20)
VAQTA™ (Hepatitis A Vaccine, inactivated [HAVi]; Merck & Co., Inc., Kenilworth, NJ, USA) is currently licensed for prevention of disease caused by hepatitis A virus in persons ≥12 months of age. This report summarizes statistical models developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6326539e9f2dece20740f2e0cb3e81d8
https://pubmed.ncbi.nlm.nih.gov/33867215
https://pubmed.ncbi.nlm.nih.gov/33867215
Publikováno v:
Vaccine. 39(9)
Background DTaP-IPV-Hib-HepB is a fully-liquid, hexavalent combination vaccine (Vaxelis™) approved for vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3d06caedc121ee12ff80b8ee0b1cc0
https://pubmed.ncbi.nlm.nih.gov/33541794
https://pubmed.ncbi.nlm.nih.gov/33541794
Autor:
Charles P. Andrews, Luwy Musey, Richard E. Rupp, Chitrananda Abeygunawardana, Steven D. Folkerth, Richard D. McFetridge, Rocio D. Marchese, David Greenberg, Jon E. Stek, Susan Ermlich, Jonathan Hartzel
Publikováno v:
Vaccine. 36:6875-6882
Background Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate vaccine (PCV13) plus 2 addi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0c8732f4552c121867e81dbe8a2f9c
https://doi.org/10.1016/j.vaccine.2018.03.012
https://doi.org/10.1016/j.vaccine.2018.03.012